For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Research and development | 86,011 | 45,838* | 56,473 | |
| General and administrative | 39,121 | 17,840* | 27,459 | |
| Total operating expenses | 125,132 | 63,678 | 83,932 | |
| Loss from operations | -125,132 | -63,678* | -83,932 | |
| Interest income | 6,355 | 7,271* | 5,736 | |
| Interest expense | 1,823 | 1,651* | 1,960 | |
| Other (expense) income, net | -432 | -678* | -137 | |
| Total other income, net | 4,100 | 4,942* | 3,639 | |
| Loss before provision for income taxes | - | -58,736* | - | |
| Provision for income taxes | - | 0* | - | |
| Net loss | -121,032 | -58,736* | -80,293 | |
| Change in unrealized losss and gaines on marketable securities | -942 | -669* | 354 | |
| Comprehensive loss | -121,974 | -59,405 | -79,939 | |
| Basic EPS | -1.69 | -0.919 | -1.26 | |
| Diluted EPS | -1.69 | -0.919 | -1.26 | |
| Basic Average Shares | 71,476,595 | 64,620,573 | 63,847,055 | |
| Diluted Average Shares | 71,476,595 | 64,620,573 | 63,847,055 | |
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)